FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) KOL and Analyst Day Call July 24, 2024 8:00 AM ET Company Participants James Caruso - President and Chief Executive Officer Sikander Ailawadhi - Professor of Medicine at Mayo Clinic Michael Morris - Co-Founder of United Theranostics and the Medical Director of Advanced Molecular Imaging and Therapy and United Theranostic Centers of Excellence Jarrod Longcor - Chief Operating Officer Conference Call Participants Edward Tenthoff - Piper Sandler Jeff Jones - Oppenheim ...

FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapeutic candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that received at leas ...

56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab) FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerci ...

Core Viewpoint - Cellectar Biosciences, Inc. has announced the issuance of new warrants that could generate significant gross proceeds, which will support the commercialization of its lead asset, iopofosine I 131, for cancer treatment [1][2][7]. Group 1: New Warrants and Financial Proceeds - The new warrants consist of Tranche A, B, and C, with potential gross proceeds of approximately $73.3 million if fully exercised [1][7]. - Tranche A warrants can generate up to $17.0 million at an exercise price of $2.52, triggered by the FDA's assignment of a review date for iopofosine I 131 [1]. - Tranche B warrants can yield approximately $32.9 million at an exercise price of $4.00, triggered by FDA approval of iopofosine I 131 [1]. - Tranche C warrants can provide about $23.5 million at an exercise price of $5.50, triggered by domestic quarterly revenue from iopofosine I 131 exceeding $10.0 million [1]. - The exercised Tranche B warrants and newly purchased warrants will generate gross proceeds of approximately $19.4 million [7]. Group 2: Product Pipeline and Development Plans - Cellectar is focused on the development of iopofosine I 131, a small-molecule PDC designed for targeted delivery of iodine-131 for cancer treatment [3][10]. - The company plans to file a New Drug Application (NDA) for iopofosine I 131 for the treatment of Waldenstrom's macroglobulinemia in Q4 2024, seeking priority review [2].

Group 1 - Cellectar Biosciences, Inc. has announced the exercise of the majority of Tranche B warrants for Series E preferred stock, generating gross proceeds of approximately $19.4 million, with potential additional proceeds of up to $73.3 million from newly purchased warrants [1][2][11] - The company plans to file a New Drug Application (NDA) for iopofosine I 131 for the treatment of Waldenstrom's macroglobulinemia in Q4 2024, seeking priority review [2] - Cellectar focuses on the development of proprietary drugs for cancer treatment using its Phospholipid Drug Conjugate™ (PDC) delivery platform, aiming for improved efficacy and safety [3][13] Group 2 - The new warrants include Tranche A, B, and C, with Tranche A potentially generating approximately $17.0 million, Tranche B approximately $32.9 million, and Tranche C approximately $23.5 million based on specific exercise triggers [11] - The company's product pipeline features lead asset iopofosine I 131, designed for targeted delivery of iodine-131, along with other preclinical PDC chemotherapeutic programs and partnered assets [13]

The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and full results. Details are as follows: A replay of the conference call will be available on the Events section of the company's investor relations website. Waldenstrom's macroglobulinemia is a B-cell malignancy characterized by bone marrow infiltration of clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. T ...

Group 1: Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform to enhance efficacy and safety [3][4]. - The company's product pipeline includes its lead asset, iopofosine I 131, designed for targeted delivery of iodine-131, along with other preclinical PDC chemotherapeutic programs and partnered assets [3]. Group 2: Industry Context - Waldenstrom's macroglobulinemia is a B-cell malignancy with approximately 26,000 prevalent cases in the US, with 1,500-1,900 new diagnoses annually [2]. - There is a significant unmet need for new FDA-approved treatments for patients with Waldenstrom's macroglobulinemia, particularly those who have progressed on BTKi therapy, as current options do not provide complete response rates and require continuous treatment [2]. - Approximately 50% of third-line patients not receiving treatment are likely to consider new treatment options, indicating a demand for innovative therapies that offer novel mechanisms of action and improved patient outcomes [2]. Group 3: Upcoming Events - Cellectar Biosciences will host an event on July 24, 2024, at 8:00 a.m. EDT to discuss recent data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia, the current treatment landscape, and opportunities to improve patient outcomes [4][5].

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin's Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. "We are excited to partner with Cellectar Biosciences to evaluate iopofosine in patients with mycosis fungoides," said Dr. Steven T. Rosen, executive vice president and director emeritus, Comprehensive Cancer Center and Beckman Research Institute of City of Hope. "Its unique delivery platform targeting all tumor ...

Topline Summary and Update Financial Overview As of their Q1 filing, CLRB held $41.4 million in current assets, made up mostly of $40.0 million in cash and equivalents. Their operating expenses, or cash burn, for the quarter reached $12.0 million. After recognizing an addition $9.9 million in losses due to valuation of their warrants, the net loss for the quarter was $21.6 million. Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a radiopharmaceutical-focused developmental biotech training their sites on a firs ...